Rat cardiomyocytes express a classical epithelial beta-defensin by Linde, Annika et al.
American Journal of Animal and Veterinary Sciences 3(1): 1-6, 2008 
ISSN 1557-4555 
© 2008 Science Publications 
Corresponding Author:  Tonatiuh Melgarejo, DVM MS PhD, Department of Human Nutrition, 143B Justin Hall  
 Kansas State University, Manhattan, KS 66506-1407 
1 
 
Rat Cardiomyocytes Express a Classical Epithelial Beta-Defensin 
1Annika Linde, 2Gerald H. Lushington, 1Frank Blecha and 3Tonatiuh Melgarejo 
Dept 1Anatomy & Physiology, 3Human Nutrition, Kansas State University, Manhattan, KS 66506 
2Molecular Graphics and Modeling Laboratory, University of Kansas, Lawrence, KS 66045 
 
Abstract: Beta-defensins (BDs) are classical epithelial antimicrobial peptides of immediate 
importance in innate host defense. Since recent studies have suggested that certain BDs are also 
expressed in non-traditional tissues, including whole heart homogenate, and because effector 
molecules of innate immunity and inflammation can influence the development of certain 
cardiovascular disease processes, we hypothesized that BDs are produced by cardiomyocytes as a 
local measure of cardioprotection against danger signals. Here we report that at least one rat beta-
defensin, rBD1, is expressed constitutively in cardiomyocytes specifically isolated using position-
ablation-laser-microdissection (P.A.L.M. Microlaser Technologies). RT-PCR analysis showed 
expression of a single 318 bp transcript in adult rat heart (laser-excised cardiomyocytes) and H9c2 
cells (neonatal rat heart myoblasts). Moreover, the full length cDNA of rBD1 was established, and 
translated into a putative peptide with 69 amino acid residues. The predicted amino acid sequence 
of the adult rat cardiac BD-1 peptide displayed 99% identity with the previously reported renal 
rBD1, and 88%, 53%, 53% and 50% identity with mouse, human, gorilla, and rhesus monkey BD1 
respectively. Furthermore, structural analysis of the cardiac rBD1 showed the classical six-
cysteine conserved motif of the BD family with an alpha-helix and three beta-sheets. Additionally, 
rBD1 displayed a significantly greater number of amphoteric residues than any of the human 
analogs, indicating a strong pH functional dependence in the rat. We suggest that rBD1, which 
was initially believed to be a specific epithelium-derived peptide, may be also involved in local 
cardiac innate immune defense mechanisms. 
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INTRODUCTION 
 
Defensins are master-players in innate immunity 
and one of the best characterized families of 
antimicrobial/host defense peptides identified in 
numerous species across the animal and plant kingdoms. 
To date, three categories of the defensin-family have 
been described in mammals, varying with respect to 
expression pattern and structural placement of six 
conserved cysteine residues [1]. Dissimilar to  α-
defensins - which are principally produced by 
circulatory neutrophils and Paneth cells in the gut - β-
defensins (BDs) are classical epithelium-derived 
peptides, whereas -defensins thus far have been 
reported in non-human primates only (‘mini defensins’). 
More recently, BDs have been identified in non-
epithelial cell types also, including circulatory 
polymorph nuclear cells and tissues macrophages [1-3]. 
Defensins are commonly referred to as natural 
endogenous antibiotics. Still, these important molecules 
seem to function far beyond that of simple antimicrobial 
peptides, including features such as immunomodulatory 
and anti-tumor activities. Their expression can be either 
constitutive or inducible - classically instigated via Toll-
like receptor mediated NF-κB (nuclear factor kappa-B) 
signaling secondary to pathogen associated molecular 
pattern recognition [3;4] . 
Cardiomyocytes have not traditionally been 
considered significant role-players in the orchestration 
of an innate immune response. Inflammation and innate 
immunity have, however, proven to be of major 
importance in a number of different cardiovascular 
disease processes, including atherosclerosis and 
myocarditis [5-9]. The Danger-Model of Immunity 
furthermore defines damage – more than mere 
foreignness - as the actual trigger of an innate immune 
response [10]. Moreover evidence exist that various 
sentinel cell types, including endotheliocytes, 
cardiomyocytes, fibroblasts and mast cells, can partake 
actively in an immune response along side more 
classical immune cells [9]. Local effector molecules of 
an innate immune response (incl. cardiac BDs) may thus 
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be central for cardioprotection in infectious as well as 
non-infectious disease processes. Recent studies have 
incidentally found concomitant mRNA expression of 
select beta-defensins in whole heart homogenate from 
different species, including dBD1 in mice, eBD1 in 
horses, pBD1 in pigs, and hBD3 in humans [11-14]. Rat 
beta-defensin-1 (rBD1) mRNA expression has in 
addition been reported in a number of different organs, 
including the heart, based on screening of an array of 
whole tissue homogenates in rats with diabetic 
nephropathy [15].  
Similar to other organs, the heart contains a number 
of different cell types. Even though BDs have been 
detected in heart tissue, no studies have conclusively 
documented that the cardiomyocytes are in fact the 
actual source of the BD expression. We thus surmised 
that the rBD1 expression in whole heart homogenate 
can be ascribed directly to cardiac myocytes, and also 
that this can be identified in different life-stages. The 
presence of these key effector molecules of innate 
immunity may prove central to the heart’s protective 
mechanisms towards an array of incoming dangers. This 
study provides evidence that laser-excised 
cardiomyocytes constitutively express at least one BD 
isoform.  
 
MATERIALS AND METHODS 
 
Whole heart tissue preparation: Whole hearts were 
excised from adult Wistar rats immediately after 
euthanasia, snap-frozen in liquid nitrogen and stored at -
86°C. All animal care and usage were in accordance 
with the Kansas State University IACUC (Institutional 
Animal Care and Usage) guidelines. The cryopreserved 
hearts were transferred individually to a LEICA 
CM3050 S Cryostat, and ½ cm x ½ cm tissue blocks of 
the frozen specimens were excised at -20°C. Each tissue 
block was covered with TBS™ Tissue Freezing 
Medium (Triangle Biomedical Sciences, Durham, NC), 
sectioned at 10µm, and transferred to PALM® 
MembraneSlides (Cat.No.1440-1000; P.A.L.M. 
Microlaser Technologies AG, Bernried, Germany) for a 
total number of 8-10 sections per slide. Tissue sections 
were fixed in 100% ethanol for 3 min at -20°C 
immediately prior to staining. H & E (hematoxylin and 
eosin) staining was performed using a modified H&E 
technique (IHC World) with all staining reagents kept 
on ice throughout the entire procedure. 
 
H9c2 cell culture: A rat embryonic cardiomyocyte cell 
line H9c2 was purchased through American type culture 
collection (ATCC, Cat. No. CRL-1446). Cells were 
cultured in DMEM (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, and 100 µg/ml streptomycin and grown up to 
75-80% confluence before being used for experiments. 
 
Position-Ablation-Laser Microdissection (P.A.L.M. 
Technology): The P.A.L.M. technology was used to 
selectively excise rat cardiomyocytes for further use in 
down-stream applications as described below. After H 
& E staining on ice, each P.A.L.M. MembraneSlide was 
transferred individually to the P.A.L.M.® MicroBeam 
System (P.A.L.M. Microlaser Technologies AG, 
Bernried, Germany) for micro-dissection and pressure 
catapulting. Micro-dissection was used to collect cell 
clusters containing an average of 100 cardiomyocytes 
exclusively by catapulting cells into a collecting cap 
above the slide. To preserve RNA upon catapulting of 
selected cells the collecting cap was preloaded with 
40µl of RLT buffer (Cat.No. 79216; QIAGEN, 
Valencia, CA). Once approximately 2,000 cells were 
catapulted, the cap was placed back into its original 
micro-vial and stored on ice for RNA extraction and 
further analysis. 
 
RNA Extraction: RNA from laser-excised 
cardiomyocytes as well as H9c2 cells (75% confluency) 
was isolated using the RNeasy® Micro Kit 50 (Cat.No. 
74004; QIAGEN, Valencia, CA) following 
manufacturer’s directions. RNA yield and integrity were 
assessed using a NanoDrop Spectrophotometer 
(NanoDrop, Wilmington, DE) and Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA) 
respectively. 
 
Identification and cloning of rBD1: To begin our 
identification of rat heart BD1, specific primers were 
designed using the cDNA sequence of the previously 
reported rat kidney β-defensin (GenBank 
No. AF093536): forward, 5’-TCT CTg CAC TCT ggA 
CCC TgA CTT-3’ and reverse, 5’-CAA ACC ACT gTC 
AAC TCC TgC AAC-3’. Using the designed primers 
and total RNA (from the fetal and laser-excised 
cardiomyocytes) as template, a one-step RT-PCR 
reaction was performed using 2 µg of total RNA 
purified from the cultured cells and micro-dissected 
cardiomyocytes respectively (OneStep RT-PCR Kit (25) 
Cat.No. 210210; QIAGEN, Valencia, CA). After 
electrophoresis of the PCR products on an agarose gel, a 
single band corresponding to approximately 300 bp was 
excised from the gel and the DNA isolated and cloned 
using the TA Cloning® Kit (Cat.No. K2000-01 
Invitrogen, Carlsbad, CA) and sequenced with an ABI 
3700 DNA Analyzer at the K-State Sequencing and 
Genotyping Facility (Manhattan, KS). The correct 
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sequence for the cloned product was verified by 
nucleotide sequencing. The efficiency of the RT 
procedure was standardized by assurance of comparable 
levels of the house-keeping gene GAPDH, amplified 
with PCR. 
 
Three-dimensional structural analysis of rBD1: A 
structural model was generated for the rat BD via 
homology modeling. The target structure was predicted 
via alignment to a set of three human BD templates 
(isoforms 1,2 and 3 respectively) for which 
experimental structural characterization was available 
[19;22]
.  The rat BD sequence was aligned to the human 
templates via the CLUSTAL-W program [23], using the 
Blosum 30 substitution matrix, a gap-opening penalty of 
10 and a gap-extension penalty of 0.1.  The resulting 
alignment and the corresponding three-dimensional 
human BD peptide structures were then processed via 
the Modeller program [24] to yield a structural prediction 
for the rBD1 target.  Modeller's default simulated 
annealing cycles were used for structural refinement.  
Analysis of the peptide secondary structure and surface 
characteristics was carried out on the resulting structure 
via SYBYL (SYBYL 6.9.2; The Tripos Associates, 2004, 
St. Louis, MO). 
 
RESULTS 
 
Expression of rBD-1 in laser-excised cardiomyocytes 
and H9c2 cells: Expression of rBD1 in laser-excised 
normal rat cardiomyocytes as well as fetal rat heart 
myoblasts (H9c2) was confirmed by a single 318 bp 
transcript identified by gel electrophoresis on the RT-
PCR products (Fig.1). The nucleotide sequencing results 
from the rBD-1 amplicon are shown in Fig.2. 
 
 
 
 
 
 
 
 
 
 
 
Fig.1: Tissue expression of rBD1 mRNA. 2 µg of 
total RNA were subject to RT-PCR and 10µl of 
40-cycle aplicons were separated on 2% 
agarose gel and stained with ethidium bromide. 
RT-Expected products had a 318 bp in size. 
Laser-excised cardiomyocytes (line A), and 
fetal rat heart myoblasts; H9c2 (line B). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2:  Full length cardiac rBD1 cDNA sequence 
showing the start and stop codons (bold and 
underlined). The cDNA sequence displayed a 
99% homology with the BD previously 
described in rat kidney [15] 
 
Comparison of heart rBD-1 with beta-defensins from 
other species: The open reading frame of the cardiac 
rBD cDNA was translated into a putative peptide with 
69 amino acid residues: MKTHYFLLVMLFFLFSQM 
ELGAGILTSLGRRTDQYRCLQNGGFCLRSSCPSHT
KLQGTCKPDKPNCCRS. Using CLUSTAL-W, the 
predicted amino acid sequence of the rat heart BD1 
peptide was aligned to five BDs from other species. The 
cardiac rBD1 displayed the strongest identity with the 
renal rBD1 (99%); mouse (88%); human (53%); gorilla 
(53%); and Rhesus monkey (50%) BDs (Fig.3).   
 
 
 
 
 
 
 
 
Fig.3:  Amino acid alignment of the defensin-domain 
regions of the heart rat beta defensin (HrBD1) 
with other known beta-defensins. The 
conservative cysteine residues are framed. 
GenBank accession number: rBD1 (rat): 
AF093536, dBD1 (mouse): BC024380, DEF1 
(Homo sapiens): BC047677, DEF1-like protein 
(gorilla): AAK61461, bD-1 (Macaca mulatta): 
AAK26258. 
 
Three-dimensional structural analysis of rBD-1: The 
structure of rBD1 (Fig.4) was predicted through 
alignment with three NMR solution structures of human 
beta defensins 1-3 (PDB IDs: 1KJ5, 1FD4, and 1KJ6 
respectively). The key six bridging cysteine motif was 
found to be conserved in the sequence alignment of rat 
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and human defensins, and no alignment gaps were 
observed in the core region, thus suggesting similar 
three-dimensional packing in all cases.  In terms of 
functionality, the rat structure was found to be much 
more similar to hBD1 (53% identical; 86% homologous 
over the core 36 aligned residues) compared to either 
hBD2 (35% identical; 59% homologous over 37 core 
residues) or hBD3 (32% identical; 59% homologous 
over 37 residues).  Within the core region, rBD1 and 
hBD1 displayed the same charge (+4 at pH = 7.0) 
comparable to that of hBD2 (+5), but significantly less 
than that of hBD3 (+8).  rBD1 displayed a significantly 
greater number of amphoteric residues (6 histidines, 
asparagines and glutamines) than any of the human 
analogs (4 for hBD1, 2 each for hBD2 and hBD3). In 
place of these extra amphoteric residues were additional 
hydroxyl amino acids in the case of hBD1, nonpolar and 
hydrophobic species for hBD2 and bases for hBD3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4:  Secondary structure assignment and surface 
analysis for rBD1 and hBD1. (A) Ribbon 
diagrams showing alpha-helix (purple), beta-
sheet (yellow), and coil (turquoise) secondary 
structure elements for the two peptides. (B) 
Front and back views of peptide solvent 
accessible surfaces. Acidic (anionic) residues 
are red, basic (cationic) residues are blue, and 
hydrophobic residues are yellow. 
 
DISCUSSION 
 
Innate immunity and inflammation have become 
central themes of investigations into a range of different 
disease processes, including common cardiovascular 
pathologies such as atherosclerosis and chronic heart 
failure [16]. Continual identification of specific effector 
molecules and immunological pathways potentially 
contributing to the development of such ailments is 
therefore indicated. The classical perception of the 
immune system as a complex but somewhat fixed entity 
of specialized organs, vessels and cells reacting in 
response to pathogens only has changed. A modernized 
view recognizes “danger” - more than foreignness - as 
the actual trigger mechanism of immunity, while also 
acknowledging the importance of non-immune cells and 
organs in host defense [9;10].  
The heart possesses a germ-line encoded innate 
stress system, which is activated in response to different 
types of injury [6]. Recent studies have focused on the 
role of individual cytokines in development of cardiac 
disease and heart failure [7]. Attention has also been 
directed at identifying different toll-like receptors 
(TLRs) in the heart, and their potential implication in 
cardiovascular pathology [17]. TLRs are classical pattern 
recognition receptors utilizing NFκB-signaling – a 
shared pathway for induction of pro-inflammatory 
cytokines as well as BDs [3;18]. BDs play a significant 
role in host defense, and some are up-regulated in 
disease [1;3]. No studies have, however, focused on 
specifically identifying the expression pattern of heart 
BDs and their potential role in cardiac health and 
disease.  
Our findings demonstrate the specific expression of 
a classically known epithelium-derived natural 
antibiotic peptide (β−defensin) in non-epithelial cells 
(rat cardiomyocytes). By using the P.A.L.M. 
MicroBeam System, we were able to specifically excise 
clusters of cardiomyocytes in a non-contact, non-heat-
producing fashion. This allowed us to perform gene 
expression studies on one specific cell type from the rat 
heart. The local expression of cardiac BDs may play a 
central role within an intrinsic innate immune response 
of the heart. Contextual studies are warranted to 
investigate the actual role of beta-defensins in 
cardiomyocytes further. It may be speculated that 
cardiac BDs act as a “second line of defense” within the 
framework of an innate immune response providing 
cardiomyocytes with a self-preserving mechanism when 
the immediate protecting barriers of the endothelial 
lining become disintegrated by damage. The presence of 
at least one BD isoform in cardiomyocytes further 
supports the notation that the heart is capable of 
producing innate effector molecules locally, as has 
previously been reported for certain cytokines.  
Different BD isoforms have been identified within 
single organs [1], and our preliminary data indicate that 
different BD isoforms are also present in the rat 
myocardium. Generally, the BD-1 isoform is known as 
a more ubiquitous and constitutively expressed isoform 
compared to other known BDs [19]. The antimicrobial 
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activity of this isoform is, however, potentially limited 
as it is not inducible by LPS [19-21]. It is possible that 
rBD1 act primarily as a local myocardial storage that 
can be mobilized and transformed into other BD 
isoforms with higher antimicrobial activities. A higher 
number of amphoteric sites in the rBD1 compared to 
hBDs would on the other hand indicate a strong pH 
functional dependence in rat relative to the human 
counterparts. Studies focused on tissues other than heart 
have shown that rBD1 is not directly up-regulated by 
the presence of certain bacterial components [20;21]. It has 
furthermore been suggested, that over-expression of 
rBD1 may play a role in diabetic nephropathy in rats [15]. 
Based on the structural analysis of rBD1 it may, 
however, be hypothesized that the acid-base status in 
tissues may play a central role for the functional 
properties of this antimicrobial peptide. Alternatively, 
this isoform may possess other yet to be identified 
specific functional characteristics of potential 
significance in cardioprotection against non-infectious 
insults.  
The present study is the first to not only identify a 
classical epithelial BD (rBD1) in cardiomyocytes from 
rat specifically isolated using position-ablation-laser-
microdissection, but also to demonstrate BD expression 
in embryonic cardiac tissue from rat. Investigation of 
BD expression in laser-excised cardiomyocytes is novel 
as it virtually eliminates the potential cross-
contamination from other types of cells within the heart. 
Further investigations are warranted to identify the 
potential significance of cardiac BDs in heart disease. 
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